News & Analysis on Clinical Trial Services & Contract Research And Development
By Natalie Morrison
- Last updated on
Before joining ProtAffin, Bartley spent 10 years at Pfizer, where he recently led early clinical-stage projects in respiratory diseases.
Jason Slingsby, CEO of ProtAffin said: “Mike’s experience gained at leading pharmaceutical companies significantly strengthens our preclinical and clinical development expertise.
“His background is ideally suited to bringing PA401, our IL-8 decoy product for neutrophilic lung diseases including COPD, into clinical development in 2012, marking our transition into a development-focused biotechnology company.”